JP2012513214A5 - - Google Patents

Download PDF

Info

Publication number
JP2012513214A5
JP2012513214A5 JP2011543606A JP2011543606A JP2012513214A5 JP 2012513214 A5 JP2012513214 A5 JP 2012513214A5 JP 2011543606 A JP2011543606 A JP 2011543606A JP 2011543606 A JP2011543606 A JP 2011543606A JP 2012513214 A5 JP2012513214 A5 JP 2012513214A5
Authority
JP
Japan
Prior art keywords
seq
binding protein
antigen binding
group
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011543606A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012513214A (ja
JP5761805B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/068858 external-priority patent/WO2010075238A1/en
Publication of JP2012513214A publication Critical patent/JP2012513214A/ja
Publication of JP2012513214A5 publication Critical patent/JP2012513214A5/ja
Application granted granted Critical
Publication of JP5761805B2 publication Critical patent/JP5761805B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011543606A 2008-12-23 2009-12-18 ヒトcgrp受容体結合タンパク質 Active JP5761805B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US20356908P 2008-12-23 2008-12-23
US61/203,569 2008-12-23
US26462209P 2009-11-25 2009-11-25
US61/264,622 2009-11-25
PCT/US2009/068858 WO2010075238A1 (en) 2008-12-23 2009-12-18 Human cgrp receptor binding proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014164088A Division JP6261132B2 (ja) 2008-12-23 2014-08-12 ヒトcgrp受容体結合タンパク質

Publications (3)

Publication Number Publication Date
JP2012513214A JP2012513214A (ja) 2012-06-14
JP2012513214A5 true JP2012513214A5 (enExample) 2013-02-07
JP5761805B2 JP5761805B2 (ja) 2015-08-12

Family

ID=41718325

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2011543606A Active JP5761805B2 (ja) 2008-12-23 2009-12-18 ヒトcgrp受容体結合タンパク質
JP2014164088A Active JP6261132B2 (ja) 2008-12-23 2014-08-12 ヒトcgrp受容体結合タンパク質
JP2015219157A Withdrawn JP2016026224A (ja) 2008-12-23 2015-11-09 ヒトcgrp受容体結合タンパク質
JP2018246704A Withdrawn JP2019062907A (ja) 2008-12-23 2018-12-28 ヒトcgrp受容体結合タンパク質
JP2020196689A Withdrawn JP2021036912A (ja) 2008-12-23 2020-11-27 ヒトcgrp受容体結合タンパク質
JP2023101810A Active JP7584577B2 (ja) 2008-12-23 2023-06-21 ヒトcgrp受容体結合タンパク質

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2014164088A Active JP6261132B2 (ja) 2008-12-23 2014-08-12 ヒトcgrp受容体結合タンパク質
JP2015219157A Withdrawn JP2016026224A (ja) 2008-12-23 2015-11-09 ヒトcgrp受容体結合タンパク質
JP2018246704A Withdrawn JP2019062907A (ja) 2008-12-23 2018-12-28 ヒトcgrp受容体結合タンパク質
JP2020196689A Withdrawn JP2021036912A (ja) 2008-12-23 2020-11-27 ヒトcgrp受容体結合タンパク質
JP2023101810A Active JP7584577B2 (ja) 2008-12-23 2023-06-21 ヒトcgrp受容体結合タンパク質

Country Status (42)

Country Link
US (7) US9102731B2 (enExample)
EP (4) EP3184546B8 (enExample)
JP (6) JP5761805B2 (enExample)
KR (4) KR101740615B1 (enExample)
CN (2) CN106084045B (enExample)
AR (1) AR074857A1 (enExample)
AU (2) AU2009330175C1 (enExample)
BR (2) BRPI0922505B1 (enExample)
CA (1) CA2746858C (enExample)
CL (1) CL2011001578A1 (enExample)
CO (1) CO6400232A2 (enExample)
CR (1) CR20110400A (enExample)
CY (3) CY1119465T1 (enExample)
DK (3) DK2379594T3 (enExample)
EA (2) EA031320B1 (enExample)
ES (3) ES2643835T3 (enExample)
FI (1) FI3569620T3 (enExample)
HR (3) HRP20250807T8 (enExample)
HU (4) HUE072123T2 (enExample)
IL (2) IL213429A (enExample)
JO (2) JO3382B1 (enExample)
LT (4) LT3569620T (enExample)
LU (1) LUC00095I2 (enExample)
MA (1) MA32982B1 (enExample)
ME (1) ME03601B (enExample)
MX (1) MX2011006804A (enExample)
MY (1) MY180564A (enExample)
NL (1) NL300961I2 (enExample)
NO (2) NO2379594T3 (enExample)
NZ (2) NZ623541A (enExample)
PE (1) PE20120427A1 (enExample)
PL (3) PL3569620T3 (enExample)
PT (3) PT3184546T (enExample)
RS (3) RS56567B1 (enExample)
SG (2) SG10201401879TA (enExample)
SI (3) SI3184546T1 (enExample)
SM (1) SMT201700504T1 (enExample)
TN (1) TN2011000283A1 (enExample)
TW (4) TWI754176B (enExample)
UA (1) UA108066C2 (enExample)
WO (1) WO2010075238A1 (enExample)
ZA (1) ZA201105418B (enExample)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5123197B2 (ja) 2005-11-14 2013-01-16 ライナット ニューロサイエンス コーポレイション カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体およびその使用方法
AU2008330125B2 (en) * 2007-11-21 2012-11-22 Amgen Inc. Wise binding antibodies and epitopes
JP5537441B2 (ja) 2008-03-04 2014-07-02 ファイザー・リミテッド 慢性疼痛を治療する方法
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
KR101519192B1 (ko) 2009-08-28 2015-05-11 리나트 뉴로사이언스 코프. 칼시토닌 유전자-관련된 펩티드에 대해 지시된 길항제 항체의 투여에 의한 내장 통증의 치료 방법
EP3662932B1 (en) 2011-05-20 2021-04-07 H. Lundbeck A/S Anti-cgrp compositions and use thereof
NZ732970A (en) 2011-05-20 2022-08-26 H Lundbeck As Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
CN103957935B (zh) 2011-05-20 2018-04-03 奥尔德生物控股有限责任公司 抗cgrp或抗cgrp‑r抗体或抗体片段用于治疗或预防慢性和急性形式的腹泻的用途
JP6469644B2 (ja) * 2013-03-15 2019-02-13 アムジエン・インコーポレーテツド 抗ccr7抗原結合タンパク質に関係する方法および組成物
TWI636064B (zh) 2013-03-15 2018-09-21 安美基公司 人類pac1抗體
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
EP4610368B1 (en) 2013-08-05 2026-02-04 Twist Bioscience Corporation De novo synthesized gene libraries
EP3957345B1 (en) 2013-10-24 2025-12-10 Amgen Inc. Drug delivery system with temperature-sensitive control
CA2920894C (en) 2013-10-24 2023-03-14 Amgen Inc. Injector and method of assembly
US10994112B2 (en) 2014-02-05 2021-05-04 Amgen Inc. Drug delivery system with electromagnetic field generator
HRP20240159T1 (hr) 2014-03-21 2024-04-12 Teva Pharmaceuticals International Gmbh Antagonistička protutijela usmjerena protiv peptida povezanog s genom kalcitonina i postupci koji ih koriste
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
MX388536B (es) 2014-05-07 2025-03-20 Amgen Inc Autoinyector con elementos reductores del shock.
CN106470717B (zh) 2014-06-03 2020-09-11 安姆根有限公司 药物递送系统和使用方法
CA2960756C (en) 2014-09-15 2023-08-01 Amgen Inc. Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
AU2015332557B2 (en) 2014-10-14 2020-05-14 Amgen Inc. Drug injection device with visual and audio indicators
EP3848072A1 (en) 2014-12-19 2021-07-14 Amgen Inc. Drug delivery device with proximity sensor
ES2785311T3 (es) 2014-12-19 2020-10-06 Amgen Inc Dispositivo de administración de fármacos con botón móvil o campo de interfaz de usuario
AU2016206457B2 (en) 2015-01-16 2021-11-11 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ROR1
WO2016126882A1 (en) 2015-02-04 2016-08-11 Twist Bioscience Corporation Methods and devices for de novo oligonucleic acid assembly
CA3069716C (en) 2015-02-17 2021-11-09 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
EP3261690B1 (en) 2015-02-27 2021-12-15 Amgen Inc. Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
US9981239B2 (en) 2015-04-21 2018-05-29 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
TWI799849B (zh) * 2015-04-24 2023-04-21 美商安美基公司 治療或預防偏頭痛之方法
WO2016183479A1 (en) 2015-05-13 2016-11-17 The Board Of Regents Of The University Of Oklahoma Variants of adrenomedullin and calcitonin gene-related peptide and methods of use
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
IL258164B (en) 2015-09-18 2022-09-01 Twist Bioscience Corp Methods for modulating protein and cellular activity and method for nucleic acid synthesis
CN108698012A (zh) 2015-09-22 2018-10-23 特韦斯特生物科学公司 用于核酸合成的柔性基底
WO2017100501A1 (en) 2015-12-09 2017-06-15 Amgen Inc. Auto-injector with signaling cap
US11154661B2 (en) 2016-01-06 2021-10-26 Amgen Inc. Auto-injector with signaling electronics
CA3012827A1 (en) 2016-02-02 2017-08-10 Fred Hutchinson Cancer Research Center Anti-ror1 antibodies and uses thereof
WO2017160799A1 (en) 2016-03-15 2017-09-21 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
CA3020839A1 (en) 2016-04-15 2017-10-19 Alder Biopharmaceuticals, Inc. Anti-pacap antibodies and uses thereof
WO2017189089A1 (en) 2016-04-29 2017-11-02 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
AU2017263558B2 (en) 2016-05-13 2022-12-22 Amgen Inc. Vial sleeve assembly
EP3458988B1 (en) 2016-05-16 2023-10-18 Amgen Inc. Data encryption in medical devices with limited computational capability
WO2017209899A1 (en) 2016-06-03 2017-12-07 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
WO2018004842A1 (en) 2016-07-01 2018-01-04 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
JP6871364B2 (ja) 2016-09-21 2021-05-12 ツイスト バイオサイエンス コーポレーション 核酸に基づくデータ保存
KR20220031944A (ko) 2016-09-23 2022-03-14 테바 파마슈티컬스 인터내셔널 게엠베하 불응성 편두통의 치료
MX2019003338A (es) 2016-09-23 2019-09-26 Teva Pharmaceuticals Int Gmbh Tratamiento de cefalea en racimos.
WO2018081234A1 (en) 2016-10-25 2018-05-03 Amgen Inc. On-body injector
US11993645B2 (en) 2017-01-11 2024-05-28 The Board Of Trustees Of The Leland Stanford Junior University Compositions comprising R-Spondin (RSPO) surrogate molecules
JP2020503976A (ja) 2017-01-17 2020-02-06 アムジエン・インコーポレーテツド 注入デバイスならびに関連する使用および組立方法
JP7305543B2 (ja) 2017-01-26 2023-07-10 スロゼン オペレーティング, インコーポレイテッド 組織特異的Wntシグナル増強分子およびその使用
MX2019009625A (es) 2017-02-17 2019-10-09 Amgen Inc Dispositivo de administracion de farmacos con trayectoria de flujo de fluido esteril y metodo relacionado de ensamblaje.
EP3582829A1 (en) 2017-02-17 2019-12-25 Amgen Inc. Insertion mechanism for drug delivery device
EP4556433A3 (en) 2017-02-22 2025-08-06 Twist Bioscience Corporation Nucleic acid based data storage
WO2018160897A1 (en) * 2017-03-02 2018-09-07 Beth Israel Deaconess Medical Center, Inc. Preventing post-ictal headaches
EP3592403B1 (en) 2017-03-06 2025-08-20 Amgen Inc. Drug delivery device with activation prevention feature
CA3052482A1 (en) 2017-03-07 2018-09-13 Amgen Inc. Needle insertion by overpressure
AU2018230486B2 (en) 2017-03-09 2023-05-11 Amgen Inc. Insertion mechanism for drug delivery device
CN118743804A (zh) 2017-03-28 2024-10-08 美国安进公司 柱塞杆和注射器组件系统以及方法
AU2018280054B2 (en) 2017-06-08 2023-07-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
CA3066399A1 (en) 2017-06-08 2018-12-13 Amgen Inc. Torque driven drug delivery device
AU2018288604B2 (en) 2017-06-22 2023-12-21 Amgen Inc. Device activation impact/shock reduction
MA49461A (fr) 2017-06-23 2020-04-29 Amgen Inc Dispositif électronique d'administration de médicament comprenant un bouchon activé par un ensemble commutateur
MA49562A (fr) 2017-07-14 2020-05-20 Amgen Inc Système d'insertion-rétractation d'aiguille présentant un système à ressort en double torsion
US11672733B2 (en) 2017-07-21 2023-06-13 Amgen Inc. Gas permeable sealing member for drug container and methods of assembly
US11484648B2 (en) 2017-07-25 2022-11-01 Amgen Inc. Drug delivery device with container access system and related method of assembly
JP2020528296A (ja) 2017-07-25 2020-09-24 アムジエン・インコーポレーテツド ギヤモジュールを有する薬物送達デバイス及び関連する組立方法
WO2019032482A2 (en) 2017-08-09 2019-02-14 Amgen Inc. HYDRAULIC-PNEUMATIC PRESSURE CHAMBER DELIVERY SYSTEM
WO2019036181A1 (en) 2017-08-18 2019-02-21 Amgen Inc. BODY INJECTOR WITH STERILE ADHESIVE PATCH
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
ES2939292T3 (es) 2017-10-04 2023-04-20 Amgen Inc Adaptador de flujo para dispositivo de administración de fármacos
EP4257164A3 (en) 2017-10-06 2024-01-17 Amgen Inc. Drug delivery device with interlock assembly and related method of assembly
EP3694578B1 (en) 2017-10-09 2025-09-24 Amgen Inc. Drug delivery device with drive assembly and related method of assembly
KR102889470B1 (ko) 2017-10-20 2025-11-21 트위스트 바이오사이언스 코포레이션 폴리뉴클레오타이드 합성을 위한 가열된 나노웰
MA50528A (fr) 2017-11-03 2020-09-09 Amgen Inc Systèmes et approches pour stériliser un dispositif d'administration de médicament
WO2019089178A1 (en) 2017-11-06 2019-05-09 Amgen Inc. Drug delivery device with placement and flow sensing
US12053618B2 (en) 2017-11-06 2024-08-06 Amgen Inc. Fill-finish assemblies and related methods
IL319987A (en) 2017-11-10 2025-06-01 Amgen Inc Plungers for drug delivery devices
SG11202003004RA (en) 2017-11-16 2020-04-29 Amgen Inc Door latch mechanism for drug delivery device
US10738110B2 (en) 2018-01-12 2020-08-11 Amgen Inc. PAC1 antibodies and uses thereof
MX2020010320A (es) 2018-04-02 2021-01-08 Amgen Inc Composiciones de erenumab y usos de las mismas.
WO2019199476A1 (en) 2018-04-12 2019-10-17 Amgen Inc. Methods for making stable protein compositions
WO2019222706A1 (en) 2018-05-18 2019-11-21 Twist Bioscience Corporation Polynucleotides, reagents, and methods for nucleic acid hybridization
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
WO2020014271A1 (en) 2018-07-09 2020-01-16 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses
US12042645B2 (en) 2018-07-24 2024-07-23 Amgen Inc. Delivery devices for administering drugs
US12115360B2 (en) 2018-07-24 2024-10-15 Amgen Inc. Hybrid drug delivery devices with grip portion
US12303677B2 (en) 2018-07-24 2025-05-20 Amgen Inc. Hybrid drug delivery devices with optional grip portion and related method of preparation
MX2021000749A (es) 2018-07-24 2021-03-29 Amgen Inc Dispositivos de suministro para administrar farmacos.
EP3829692A1 (en) 2018-07-31 2021-06-09 Amgen Inc. Fluid path assembly for a drug delivery device
US20210346601A1 (en) 2018-09-24 2021-11-11 Amgen Inc. Interventional dosing systems and methods
EP3856283A1 (en) 2018-09-28 2021-08-04 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
AU2019352616B2 (en) 2018-10-02 2024-10-10 Amgen Inc. Injection systems for drug delivery with internal force transmission
US12151089B2 (en) 2018-10-05 2024-11-26 Amgen Inc. Drug delivery device having dose indicator
SG11202103800RA (en) 2018-10-15 2021-05-28 Amgen Inc Drug delivery device having damping mechanism
JP2022504805A (ja) 2018-10-15 2022-01-13 アムジエン・インコーポレーテツド 薬物送達デバイスのプラットフォーム式組み立てプロセス
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
US11213620B2 (en) 2018-11-01 2022-01-04 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
AU2019370159B2 (en) 2018-11-01 2025-05-29 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
CA3124980A1 (en) 2018-12-26 2020-07-02 Twist Bioscience Corporation Highly accurate de novo polynucleotide synthesis
US11639380B2 (en) * 2019-01-08 2023-05-02 H. Lundbeck A/S Acute treatment and rapid treatment of headache using anti-CGRP antibodies
JP2022521551A (ja) * 2019-02-26 2022-04-08 ツイスト バイオサイエンス コーポレーション Glp1受容体の変異体核酸ライブラリ
CN113785057A (zh) 2019-02-26 2021-12-10 特韦斯特生物科学公司 用于抗体优化的变异核酸文库
JP7510952B2 (ja) 2019-04-24 2024-07-04 アムジエン・インコーポレーテツド シリンジ滅菌確認アセンブリ及び方法
WO2020239014A1 (zh) * 2019-05-30 2020-12-03 山东博安生物技术有限公司 抗cgrp抗体及其应用
JP7756001B2 (ja) 2019-06-28 2025-10-17 アムジエン・インコーポレーテツド 抗cgrp受容体/抗pac1受容体二重特異性抗原結合タンパク質
JP7608439B2 (ja) 2019-08-23 2025-01-06 アムジエン・インコーポレーテツド 構成可能な針シールド係合構成要素を備えた薬物送達デバイス及び関連方法
US12091777B2 (en) 2019-09-23 2024-09-17 Twist Bioscience Corporation Variant nucleic acid libraries for CRTH2
WO2021061842A1 (en) 2019-09-23 2021-04-01 Twist Bioscience Corporation Variant nucleic acid libraries for single domain antibodies
CA3077973A1 (en) 2020-04-06 2021-10-06 H. Lundbeck A/S Treatment of most bothersome symptom (mbs) associated with migraine using anti-cgrp antibodies
JP2023549854A (ja) 2020-11-16 2023-11-29 スロゼン オペレーティング, インコーポレイテッド 肝臓特異的Wntシグナル増強分子およびその使用
JP2024509165A (ja) 2021-03-02 2024-02-29 シージーアールピー ダイアグノスティクス ゲーエムベーハー 片頭痛の治療及び/又は発生の低減
CA3217207A1 (en) 2021-05-21 2022-11-24 Amgen Inc. Method of optimizing a filling recipe for a drug container
WO2023026205A1 (en) 2021-08-24 2023-03-02 Cgrp Diagnostics Gmbh Preventative treatment of migraine
AU2023264616A1 (en) * 2022-05-05 2024-10-24 Amgen Inc. Heteromultimer binding dll3 and cd3
TW202432600A (zh) 2022-11-07 2024-08-16 美商安進公司 用於治療肥胖症之方法
WO2025226754A1 (en) 2024-04-23 2025-10-30 Amgen Inc. Method for predicting osmolality of protein solutions
CN118459595A (zh) * 2024-05-21 2024-08-09 杭州百懿生物药业有限公司 特异性结合cgrp受体的抗体分子及其用途
WO2026030152A1 (en) 2024-07-29 2026-02-05 Amgen Inc. System and method for assessing transferability of a fill recipe

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JPH02229119A (ja) 1989-02-28 1990-09-11 Toyo Jozo Co Ltd 動脈硬化予防および治療剤
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
JP3126980B2 (ja) 1991-03-11 2001-01-22 ザ・ユニバーシテイ・オブ・ジヨージア・リサーチ・フアウンデーシヨン・インコーポレーテツド レニラ(renilla)ルシフェラーゼのクローニング及び発現
CA2111348A1 (en) 1991-06-14 1992-12-23 John S. Logan Production of human hemoglobin in transgenic pigs
JPH06508880A (ja) 1991-07-08 1994-10-06 ユニバーシティ オブ マサチューセッツ アット アムハースト サーモトロピック液晶セグメント化ブロックコポリマー
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
CA2130173A1 (en) * 1992-03-17 1993-09-30 Norman Hardman Genetically engineered antibodies
JPH07509137A (ja) 1992-07-24 1995-10-12 セル ジェネシス,インク. 異種抗体の生産
WO1994010308A1 (en) 1992-10-23 1994-05-11 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5766880A (en) 1992-10-27 1998-06-16 Queen's University At Kingston Isolated nucleic acid molecules encoding multidrug resistance proteins
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
AU694745B2 (en) 1993-09-10 1998-07-30 Trustees Of Columbia University In The City Of New York, The Uses of green fluorescent protein
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
WO1996003993A2 (en) 1994-08-05 1996-02-15 The Rockefeller University Modulation of thymocyte and t cell functional activity
ATE265466T1 (de) * 1994-08-16 2004-05-15 Human Genome Sciences Inc Calcitoninrezeptor
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
AU6596096A (en) 1996-07-23 1998-02-10 Smithkline Beecham Corporation Calcitonin gene-related peptide receptor component factor (houdc44)
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
US6255455B1 (en) * 1996-10-11 2001-07-03 The Trustees Of The University Of Pennsylvania Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US6458547B1 (en) 1996-12-12 2002-10-01 Prolume, Ltd. Apparatus and method for detecting and identifying infectious agents
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
DE19732944A1 (de) 1997-07-31 1999-02-04 Thomae Gmbh Dr K Peptidische CGRP-Antagonisten
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
EP1064360B1 (en) 1998-03-27 2008-03-05 Prolume, Ltd. Luciferases, gfp fluorescent proteins, their nucleic acids and the use thereof in diagnostics
US6268474B1 (en) 1998-04-30 2001-07-31 Creighton University Peptide antagonists of CGRP-receptor superfamily and methods of use
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
US20020142374A1 (en) 1998-08-17 2002-10-03 Michael Gallo Generation of modified molecules with increased serum half-lives
EP1234174A1 (en) * 1999-12-02 2002-08-28 Myriad Genetics, Inc. Protein-protein interactions
US20020090646A1 (en) 2000-05-03 2002-07-11 Amgen Inc. Calcitonin-related molecules
FR2821080B1 (fr) 2001-02-20 2003-12-19 Sanofi Synthelabo Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques
CA2450793A1 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
JP4603261B2 (ja) * 2001-09-27 2010-12-22 メルク・シャープ・エンド・ドーム・コーポレイション ヒト化カルシトニン遺伝子関連ペプチド受容体をコードする単離dna分子、関連する非ヒトトランスジェニック動物及びアッセイ方法
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
EP1576112B1 (en) * 2002-01-18 2012-02-29 ZymoGenetics, Inc. Cytokine receptor zcytor17 multimers
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20040110170A1 (en) * 2002-05-18 2004-06-10 The Regents Of The University Of California Cloning and characterization of calcitonin gene related peptide receptors
US20070071744A1 (en) * 2002-06-07 2007-03-29 Gotz Munch Agents which bind to epitopes of glycoprotein VI
PL375536A1 (en) * 2002-08-12 2005-11-28 Birkir Sveinsson Use of cgrp antagonist compounds for treatment of psoriasis
US20040176577A1 (en) * 2002-09-10 2004-09-09 Eva Rojer Immunoassays for specific determination of SCCA isoforms
WO2004097421A2 (en) 2003-04-29 2004-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with calcitonin receptor-like receptor (calcrl)
BRPI0507594A (pt) 2004-02-11 2007-07-03 Amylin Pharmaceuticals Inc polipetìdeos hìbridos com propriedades selecionáveis
US7423128B2 (en) * 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
WO2006068953A2 (en) * 2004-12-21 2006-06-29 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
US9072777B2 (en) 2005-06-16 2015-07-07 Takayuki Shindo Method for screening substance having proangiogenic effect
GB0521139D0 (en) 2005-10-18 2005-11-23 Univ Sheffield Therapeutic agent
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
JP5123197B2 (ja) 2005-11-14 2013-01-16 ライナット ニューロサイエンス コーポレイション カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体およびその使用方法
WO2007076336A1 (en) * 2005-12-22 2007-07-05 Eli Lilly And Company Treatment of migraine with anti-cgrp antibodies
EP2064244B1 (en) * 2006-08-03 2019-06-05 MedImmune Limited ANTIBODIES DIRECTED TO alphaVbeta6 AND USES THEREOF
GB0708002D0 (en) 2007-04-25 2007-06-06 Univ Sheffield Antibodies
DK2265288T3 (en) 2008-03-04 2016-06-06 Labrys Biologics Inc Methods for the treatment of inflammatory pain
FR2934597B1 (fr) * 2008-07-31 2013-04-19 Univ Aix Marseille Ii Anticorps se liant aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament.
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
KR101519192B1 (ko) 2009-08-28 2015-05-11 리나트 뉴로사이언스 코프. 칼시토닌 유전자-관련된 펩티드에 대해 지시된 길항제 항체의 투여에 의한 내장 통증의 치료 방법
US9401875B2 (en) 2012-06-01 2016-07-26 Nippon Telegraph And Telephone Corporation Packet transfer processing method and packet transfer processing device
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof
CA2960756C (en) 2014-09-15 2023-08-01 Amgen Inc. Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
TWI799849B (zh) 2015-04-24 2023-04-21 美商安美基公司 治療或預防偏頭痛之方法
US11385238B2 (en) * 2017-06-30 2022-07-12 Amgen Inc. Methods of protein clips recovery
MX2020010320A (es) * 2018-04-02 2021-01-08 Amgen Inc Composiciones de erenumab y usos de las mismas.

Similar Documents

Publication Publication Date Title
JP2012513214A5 (enExample)
AU2019232762B2 (en) Anti-claudin 18.2 antibodies and uses thereof
KR102937285B1 (ko) 신규 항-pd-l1 항체
US20220220218A1 (en) Anti-cd73 antibody, antigen-binding fragment thereof and application thereof
EP3950716A1 (en) Anti-claudin 18.2 antibody and application thereof
JP2024054266A (ja) 組織因子経路インヒビター抗体およびその使用
JP2020079252A5 (enExample)
JP2012504955A5 (enExample)
JP2017536354A5 (enExample)
US20200347130A1 (en) CD96 Antibody, Antigen-Binding Fragment and Pharmaceutical use Thereof
AU2017226510A1 (en) PDL-1 antibody, pharmaceutical composition thereof, and uses thereof
JP2018035138A5 (enExample)
JP2015503909A5 (enExample)
JP2010516229A5 (enExample)
JP2017514461A5 (enExample)
HRP20171690T1 (hr) Antitijela koja se vežu za humani cgrp receptor
JP2009545325A5 (enExample)
RU2009129403A (ru) Антитела, нейтрализующие цитомегаловирус человека, и их применение
RU2016137110A (ru) Антитела к компоненту комплемента с5
JP2015501149A5 (enExample)
CN112513094A (zh) 结合人her2的抗体、其制备方法和用途
JP2018514193A5 (enExample)
WO2023040945A1 (zh) 特异性结合pd-1的蛋白及其医药用途
KR20220042258A (ko) 항 tigit 항체 및 그의 응용
CA3208455A1 (en) Novel anti-gremlin1 antibodies